Gonadotropin‐Releasing Hormone Antagonists

Annals of the New York Academy of Sciences - Tập 943 Số 1 - Trang 49-54 - 2001
Keith Gordon1
1Reproductive Medicine, Organon Inc., West Orange, New Jersey 07052, USA

Tóm tắt

AbstractUntil recently, gonadotropin‐releasing hormone (GnRH) agonists were the only choice available to physicians for prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. The recent FDA approval of GnRH antagonists for this indication gives clinicians some new options. Results of clinical trials to date suggest that, with GnRH antagonists, much shorter treatment regimens with fewer injections and possibly less gonadotropin can achieve good clinical results. In most of the trials performed to date, however, the GnRH antagonist regimens have been associated with a slightly lower pregnancy and implantation rate than the established GnRH agonist protocols. This remains the biggest hurdle to their more general acceptance. Herein, the possible contributing factors are discussed, and the proposal made that differences in serum estradiol patterns preceding oocyte retrieval are the most likely contributing factor.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(78)92957-4

10.1016/S0015-0282(16)55430-2

10.1210/endo-129-4-1687

Schally A.V., 1971, Stimulation and inhibition of fertility through hypothalamic agents, Drug Ther., 1, 29

10.1126/science.176.4037.933

10.1016/S0010-7824(84)80008-6

10.1016/S0015-0282(99)00446-X

10.1093/humrep/14.11.2681

10.1093/humrep/14.suppl_1.207

10.1093/humrep/14.12.2959

10.1093/humrep/15.6.1211

10.1016/S0015-0282(99)00524-5

10.1093/humrep/15.3.526

10.1093/humrep/15.7.1490

10.1093/humrep/13.11.3023

10.1093/humrep/15.5.1015

10.1016/S0015-0282(16)58404-0

10.1093/humrep/14.9.2242

Thông tin
Thông tin xuất bản

Annals of the New York Academy of Sciences

Tập 943 Số 1

49-54

Thông tin tác giả